1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Perceptive Advisors Llc Buys Agios Pharmaceuticals Inc, Provention Bio Inc, Quotient, Sells Dova Pharmaceuticals Inc, Solid Biosciences Inc, Spark Therapeutics Inc

New York, NY, based Investment company Perceptive Advisors Llc (Current Portfolio) buys Agios Pharmaceuticals Inc, Provention Bio Inc, Quotient, Tandem Diabetes Care Inc, Arvinas Inc, sells Dova Pharmaceuticals Inc, Solid Biosciences Inc, Spark Therapeutics Inc, Blueprint Medicines Corp, Nevro Corp during the 3-months ended 2019Q4, according to the most recent filings of the investment company, Perceptive Advisors Llc. As of 2019Q4, Perceptive Advisors Llc owns 104 stocks with a total value of $4.9 billion. These are the details of the buys and sells.

For the details of PERCEPTIVE ADVISORS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/perceptive+advisors+llc/current-portfolio/portfolio

These are the top 5 holdings of PERCEPTIVE ADVISORS LLC
  1. Global Blood Therapeutics Inc (GBT) - 5,865,726 shares, 9.60% of the total portfolio. Shares reduced by 0.17%
  2. Mirati Therapeutics Inc (MRTX) - 3,203,406 shares, 8.50% of the total portfolio. Shares reduced by 3.35%
  3. Neurocrine Biosciences Inc (NBIX) - 3,612,554 shares, 8.00% of the total portfolio. Shares reduced by 11.02%
  4. Kodiak Sciences Inc (KOD) - 3,663,557 shares, 5.43% of the total portfolio. Shares added by 16.85%
  5. Iovance Biotherapeutics Inc (IOVA) - 9,416,202 shares, 5.37% of the total portfolio. Shares reduced by 14.51%
New Purchase: Agios Pharmaceuticals Inc (AGIO)

Perceptive Advisors Llc initiated holding in Agios Pharmaceuticals Inc. The purchase prices were between $30.08 and $50.59, with an estimated average price of $38.07. The stock is now traded at around $53.04. The impact to a portfolio due to this purchase was 0.89%. The holding were 900,000 shares as of .

New Purchase: Arvinas Inc (ARVN)

Perceptive Advisors Llc initiated holding in Arvinas Inc. The purchase prices were between $15.39 and $44.38, with an estimated average price of $29.74. The stock is now traded at around $50.86. The impact to a portfolio due to this purchase was 0.34%. The holding were 400,000 shares as of .

New Purchase: AnaptysBio Inc (ANAB)

Perceptive Advisors Llc initiated holding in AnaptysBio Inc. The purchase prices were between $10.18 and $38.96, with an estimated average price of $23.27. The stock is now traded at around $15.53. The impact to a portfolio due to this purchase was 0.33%. The holding were 1,000,000 shares as of .

New Purchase: Aurinia Pharmaceuticals Inc (AUPH)

Perceptive Advisors Llc initiated holding in Aurinia Pharmaceuticals Inc. The purchase prices were between $3.88 and $21.42, with an estimated average price of $9.42. The stock is now traded at around $20.03. The impact to a portfolio due to this purchase was 0.3%. The holding were 716,666 shares as of .

New Purchase: Revance Therapeutics Inc (RVNC)

Perceptive Advisors Llc initiated holding in Revance Therapeutics Inc. The purchase prices were between $11.66 and $20.15, with an estimated average price of $15.6. The stock is now traded at around $26.68. The impact to a portfolio due to this purchase was 0.27%. The holding were 820,377 shares as of .

New Purchase: Morphic Holding Inc (MORF)

Perceptive Advisors Llc initiated holding in Morphic Holding Inc. The purchase prices were between $13.02 and $19.5, with an estimated average price of $15.61. The stock is now traded at around $13.95. The impact to a portfolio due to this purchase was 0.23%. The holding were 650,000 shares as of .

Added: Provention Bio Inc (PRVB)

Perceptive Advisors Llc added to a holding in Provention Bio Inc by 338.46%. The purchase prices were between $5.84 and $14.9, with an estimated average price of $9.04. The stock is now traded at around $15.40. The impact to a portfolio due to this purchase was 0.69%. The holding were 2,921,574 shares as of .

Added: Quotient Ltd (QTNT)

Perceptive Advisors Llc added to a holding in Quotient Ltd by 23.17%. The purchase prices were between $7.07 and $9.51, with an estimated average price of $8.31. The stock is now traded at around $7.29. The impact to a portfolio due to this purchase was 0.49%. The holding were 13,289,054 shares as of .

Added: Tandem Diabetes Care Inc (TNDM)

Perceptive Advisors Llc added to a holding in Tandem Diabetes Care Inc by 4727.16%. The purchase prices were between $53.13 and $71.19, with an estimated average price of $61.87. The stock is now traded at around $90.04. The impact to a portfolio due to this purchase was 0.37%. The holding were 310,000 shares as of .

Added: DBV Technologies SA (DBVT)

Perceptive Advisors Llc added to a holding in DBV Technologies SA by 21.02%. The purchase prices were between $6.75 and $11.15, with an estimated average price of $8.02. The stock is now traded at around $9.67. The impact to a portfolio due to this purchase was 0.17%. The holding were 4,367,809 shares as of .

Added: Molecular Templates Inc (MTEM)

Perceptive Advisors Llc added to a holding in Molecular Templates Inc by 25.33%. The purchase prices were between $6.44 and $14.21, with an estimated average price of $9.72. The stock is now traded at around $15.58. The impact to a portfolio due to this purchase was 0.14%. The holding were 2,474,133 shares as of .

Added: Vocera Communications Inc (VCRA)

Perceptive Advisors Llc added to a holding in Vocera Communications Inc by 197.00%. The purchase prices were between $19.12 and $24.89, with an estimated average price of $21.91. The stock is now traded at around $25.80. The impact to a portfolio due to this purchase was 0.09%. The holding were 296,420 shares as of .

Sold Out: Dova Pharmaceuticals Inc (DOVA)

Perceptive Advisors Llc sold out a holding in Dova Pharmaceuticals Inc. The sale prices were between $27.98 and $28.51, with an estimated average price of $28.18.

Sold Out: Solid Biosciences Inc (SLDB)

Perceptive Advisors Llc sold out a holding in Solid Biosciences Inc. The sale prices were between $2.82 and $12.9, with an estimated average price of $7.22.

Sold Out: Spark Therapeutics Inc (ONCE)

Perceptive Advisors Llc sold out a holding in Spark Therapeutics Inc. The sale prices were between $96.25 and $113.57, with an estimated average price of $107.51.

Sold Out: Merit Medical Systems Inc (MMSI)

Perceptive Advisors Llc sold out a holding in Merit Medical Systems Inc. The sale prices were between $20.66 and $32.08, with an estimated average price of $28.67.

Sold Out: Marker Therapeutics Inc (GX1N)

Perceptive Advisors Llc sold out a holding in Marker Therapeutics Inc. The sale prices were between $2.39 and $4.27, with an estimated average price of $3.23.

Sold Out: CymaBay Therapeutics Inc (CBAY)

Perceptive Advisors Llc sold out a holding in CymaBay Therapeutics Inc. The sale prices were between $1.33 and $5.93, with an estimated average price of $3.68.

Reduced: Blueprint Medicines Corp (BPMC)

Perceptive Advisors Llc reduced to a holding in Blueprint Medicines Corp by 29.96%. The sale prices were between $66.73 and $82.59, with an estimated average price of $75.07. The stock is now traded at around $65.92. The impact to a portfolio due to this sale was -0.54%. Perceptive Advisors Llc still held 618,624 shares as of .

Reduced: Nevro Corp (NVRO)

Perceptive Advisors Llc reduced to a holding in Nevro Corp by 21.63%. The sale prices were between $76.41 and $117.54, with an estimated average price of $99.76. The stock is now traded at around $144.31. The impact to a portfolio due to this sale was -0.5%. Perceptive Advisors Llc still held 763,886 shares as of .

Reduced: Invitae Corp (NVTA)

Perceptive Advisors Llc reduced to a holding in Invitae Corp by 71.93%. The sale prices were between $15.02 and $20.57, with an estimated average price of $17.7. The stock is now traded at around $27.50. The impact to a portfolio due to this sale was -0.46%. Perceptive Advisors Llc still held 336,308 shares as of .

Reduced: Y-mAbs Therapeutics Inc (YMAB)

Perceptive Advisors Llc reduced to a holding in Y-mAbs Therapeutics Inc by 34.24%. The sale prices were between $23.81 and $33.78, with an estimated average price of $29.77. The stock is now traded at around $34.47. The impact to a portfolio due to this sale was -0.21%. Perceptive Advisors Llc still held 562,237 shares as of .

Reduced: Turning Point Therapeutics Inc (TPTX)

Perceptive Advisors Llc reduced to a holding in Turning Point Therapeutics Inc by 26.76%. The sale prices were between $35.56 and $63.25, with an estimated average price of $48.08. The stock is now traded at around $60.23. The impact to a portfolio due to this sale was -0.17%. Perceptive Advisors Llc still held 437,390 shares as of .

Reduced: Select Interior Concepts Inc (SIC)

Perceptive Advisors Llc reduced to a holding in Select Interior Concepts Inc by 76.11%. The sale prices were between $8.92 and $12.65, with an estimated average price of $10.59. The stock is now traded at around $8.15. The impact to a portfolio due to this sale was -0.12%. Perceptive Advisors Llc still held 105,105 shares as of .



Here is the complete portfolio of PERCEPTIVE ADVISORS LLC. Also check out:

1. PERCEPTIVE ADVISORS LLC's Undervalued Stocks
2. PERCEPTIVE ADVISORS LLC's Top Growth Companies, and
3. PERCEPTIVE ADVISORS LLC's High Yield stocks
4. Stocks that PERCEPTIVE ADVISORS LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)